A new white paper by Karen Mulligan provides historic context and puts the pitfalls and promise of the 340B drug pricing program into perspective. Her analysis also suggests how the program can be modified to better serve its aims of stretching federal dollars to better serve patients in need.
Other featured articles
Federal 340B Drug Pricing Policies Need Reform to Realize Potential
USC Schaeffer study finds Federal 340B Drug Pricing Program oversight needs tightening to ensure discounts reach the right safety-net providers and patients
Getting It Right: Drug Pricing Reform That Works for Patients and the Medicare Program
As Congress narrows in on prescription drug pricing reform, what policy changes should be prioritized? Join Schaeffer Center and the Alliance for Aging Research to hear from a policymaker at the center of the debate in Congress, an expert in healthcare policy research, and a leading advocate for older adults.
Biosimilars Competition Helps Patients More Than Generic Competition
Schaeffer Center Co-Director Dana Goldman argues that well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.